NLS Pharmaceutics Ltd. Warrant (NLSPW)

• Market cap: $552K
• 1 day: -22.22%
• 5 days: 52.17%
• 1 month: 204.35%
• 3 months: -6.67%
• 6 months: -11.95%
• Year to date: 16.67%
• 1 year: -44.22%
• 5 years: -98.18%
• 10 years: -98.18%
• Sector: Healthcare
• Industry: Biotechnology

About: NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 250

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.8% less ownership

Funds ownership: 1.03% [Q4 2024] → 0.22% (-0.8%) [Q1 2025]

40% less funds holding

Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]

78% less capital invested

Capital invested by funds: $5.17K [Q4 2024] → $1.14K (-$4.03K) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2